|

Petosemtamab Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since July 2026

Pipeline

Phase 3: 3

Top Sponsors

  • Merus B.V.2
  • Genmab1

Indications

  • Cancer3
  • Head and Neck Squamous Cell Carcinoma2
  • Left-sided Colorectal Cancer1

Mobile, Alabama2 trials

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Site 160

Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Site 164

Phase 3

Other1 trial

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.